The retrospective study as the 1st-line chemotherapy of fluorouracil and bevacizumab for the frail-patients with unresectable or metastatic colorectal cancer

The retrospective study as the 1st-line chemotherapy of fluorouracil and bevacizumab for the frail-patients with unresectable or metastatic colorectal cancer - The retrospective study of fluorouracil and bevacizumab for the frail-patients with colorectal cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000009503

Enrollment

Registered

2012-12-07

Start date

2012-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: aged 65 years or older with a performance status (PS) of 0-2 and met one or more of the following conditions: Serum albumin< 3.5 g/dl, past medical history of radiation of the abdominal region or pelvic cavity, and incompatibility with oxaliplatin and irinotecan

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
PFS, OS, RR, DCR, Adverse event	—

Countries

Japan

Outcome results